Exicure (XCUR) Change in Accured Expenses (2016 - 2026)
Exicure's (XCUR) quarterly Change in Accured Expenses came in at -$400000.0 in Q1 2026, down 226.58% YoY from $316000.0 in Q1 2025, and down 1718.18% on a QoQ basis from -$22000.0 in Q4 2025.
Exicure (XCUR) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Change in Accured Expenses data on file, last reported at -$400000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 226.58% year-over-year to -$400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 184.19% YoY) and the FY2025 annual result came in at -$614000.0, up 25.76% from the prior year.
- Change in Accured Expenses eased to -$400000.0 in Q1 2026, from -$22000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $316000.0 in Q1 2025 to a low of -$3.2 million in Q1 2022.
- A 5-year average of -$456176.5 and a median of -$218000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 834.88% in 2025, down 2972.73% in 2025.
- Tracing XCUR's Change in Accured Expenses over 5 years: stood at -$1.7 million in 2022, then surged by 88.95% to -$192000.0 in 2023, then decreased by 13.54% to -$218000.0 in 2024, then surged by 89.91% to -$22000.0 in 2025, then slumped by 1718.18% to -$400000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$400000.0 (Q1 2026), -$22000.0 (Q4 2025), and -$592000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -400,000.00 |
| Mar 31, 2026 | -400,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | -592,000.00 |
| Sep 30, 2025 | -592,000.00 |
| Jun 30, 2025 | -316,000.00 |
| Jun 30, 2025 | -316,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | -218,000.00 |
| Dec 31, 2024 | -218,000.00 |
| Sep 30, 2024 | -577,000.00 |
| Sep 30, 2024 | -577,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Dec 31, 2023 | -192,000.00 |
| Dec 31, 2023 | -192,000.00 |